Quick Answer
BioRestorative Therapies, Inc. reported Total Revenue of $359.7 thousand for fiscal year 2025.
BioRestorative Therapies, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $359.7K -10.3% |
$401.0K +175.0% |
$145.8K +21.7% |
$119.8K +160.4% |
$46.0K -40.3% |
$77.0K -40.8% |
| Revenue (ASC 606) | $359.7K -10.3% |
$401.0K +175.0% |
$145.8K +21.7% |
$119.8K +160.4% |
$46.0K -40.3% |
$77.0K -40.8% |
| Net Income | -$14.24M -58.6% |
-$8.98M +13.8% |
-$10.42M +43.7% |
-$18.49M +58.3% |
-$44.30M -293.0% |
-$11.27M +23.0% |
| Diluted EPS | -$1.58 -36.2% |
-$1.16 +53.0% |
-$2.47 +51.7% |
-$5.11 | — | — |
| Total Assets | $4.08M -66.8% |
$12.28M -2.6% |
$12.61M -23.3% |
$16.43M -26.8% |
$22.45M +416.5% |
$4.35M +196.5% |
| Cash and Equivalents | $1.51M +175.8% |
$547.9K -38.0% |
$884.4K -48.4% |
$1.71M -91.8% |
$21.03M | — |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $356.7K -95.8% |
$8.53M -14.7% |
$10.00M -2.8% |
$10.29M -52.4% |
$21.60M +1722.0% |
-$1.33M +89.6% |
| R&D Expense | $10.09M +50.5% |
$6.71M +66.2% |
$4.03M +14.8% |
$3.51M +381.9% |
$729.1K -16.9% |
$876.8K -49.1% |
| Operating Income | -$15.65M -35.4% |
-$11.56M +24.1% |
-$15.22M +19.8% |
-$18.97M +27.9% |
-$26.31M -855.9% |
-$2.75M +67.4% |
| Gross Profit | $335.9K -9.9% |
$372.9K +155.8% |
$145.8K | — | — | — |
| Shares Outstanding | 8.88M +28.3% |
6.92M +47.0% |
4.71M +28.0% |
3.68M +4.5% |
3.52M +392.0% |
715,544 -99.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $11.8K | -94.9% | -96.1% |
| Revenue (ASC 606) | September 30, 2025 | $11.8K | -94.9% | -96.1% |
| Net Income | September 30, 2025 | -$3.04M | -178.4% | -14.4% |
| Diluted EPS | September 30, 2025 | -$0.33 | -153.8% | -10.0% |
| Total Assets | September 30, 2025 | $5.64M | -61.3% | -33.7% |
| Cash and Equivalents | September 30, 2025 | $602.4K | -59.6% | -61.3% |
| Stockholders Equity | September 30, 2025 | $2.21M | -77.9% | -54.5% |
| R&D Expense | September 30, 2025 | $2.59M | +78.5% | +16.6% |
| Operating Income | September 30, 2025 | -$3.71M | -62.2% | -12.2% |
| Gross Profit | September 30, 2025 | $1.2K | -99.4% | -99.6% |
| Shares Outstanding | September 30, 2025 | 7.98M | +15.3% | +0.0% |
- BioRestorative Therapies, Inc. reported Total Revenue of $359.7 thousand for fiscal year 2025.
- BioRestorative Therapies, Inc. showed a decrease of -10.3% in Total Revenue compared to the prior fiscal year.
- BioRestorative Therapies, Inc. reported Revenue (ASC 606) of $359.7 thousand for fiscal year 2025.
- BioRestorative Therapies, Inc. showed a decrease of -10.3% in Revenue (ASC 606) compared to the prior fiscal year.
- BioRestorative Therapies, Inc. reported Net Income of -$14.24 million for fiscal year 2025.
- BioRestorative Therapies, Inc. showed a decrease of -58.6% in Net Income compared to the prior fiscal year.
- BioRestorative Therapies, Inc. reported Diluted EPS of $1.58 per share (loss) for fiscal year 2025.
- BioRestorative Therapies, Inc. showed a decrease of -36.2% in Diluted EPS compared to the prior fiscal year.
- BioRestorative Therapies, Inc. reported Total Assets of $4.08 million for fiscal year 2025.
- BioRestorative Therapies, Inc. showed a decrease of -66.8% in Total Assets compared to the prior fiscal year.
- BioRestorative Therapies, Inc. reported Cash and Equivalents of $1.51 million for fiscal year 2025.
- BioRestorative Therapies, Inc. showed an increase of +175.8% in Cash and Equivalents compared to the prior fiscal year.
- BioRestorative Therapies, Inc. reported Long-Term Debt of $196.9 thousand for fiscal year 2010.
- BioRestorative Therapies, Inc. reported Stockholders Equity of $356.7 thousand for fiscal year 2025.
- BioRestorative Therapies, Inc. showed a decrease of -95.8% in Stockholders Equity compared to the prior fiscal year.
- BioRestorative Therapies, Inc. reported R&D Expense of $10.09 million for fiscal year 2025.
- BioRestorative Therapies, Inc. showed an increase of +50.5% in R&D Expense compared to the prior fiscal year.
- BioRestorative Therapies, Inc. reported Operating Income of -$15.65 million for fiscal year 2025.
- BioRestorative Therapies, Inc. showed a decrease of -35.4% in Operating Income compared to the prior fiscal year.
- BioRestorative Therapies, Inc. reported Gross Profit of $335.9 thousand for fiscal year 2025.
- BioRestorative Therapies, Inc. showed a decrease of -9.9% in Gross Profit compared to the prior fiscal year.
- BioRestorative Therapies, Inc. reported Shares Outstanding of 8.88 million shares for fiscal year 2025.
- BioRestorative Therapies, Inc. showed an increase of +28.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: